Antibody Drug Conjugates Market by Drugs - Global Opportunity Analysis and Industry Forecast 2017-2023.

  • ID: 4403076
  • Report
  • Region: Global
  • 152 pages
  • Allied Analytics LLP
1 of 3
The antibody drug conjugates market was valued at $1,387 million in 2016, and is estimated to reach $3,198 million by 2023, registering a CAGR of 12.9% from 2017 to 2023. Antibody drug conjugates (ADC’s) are promising and effective anticancer medications employed for efficient treatment of cancer patients. ADC’s are biopharmaceutical drugs prepared by integrating two clinical approaches viz cell killing HPAPI (powerful pharmaceutical ingredient) and monoclonal antibody specificity. This combination approach enables elimination of cancer infected cells without harming healthy cells in patient’s body.

Increase in global prevalence of cancer and demand for quality & cost-effective cancer medications drives the global ADCs market. In addition, extensive R&D for cancer medication and approval of new cancer drugs is expected to boost the market growth during the forecast period. However, high cost involved in R&D of cancer medication and stringent government regulations impedes the growth of antibody drug conjugates market.

The report segments the market based on drugs, mechanism of action, application, and region. Based on drugs, the market is bifurcated into Adcetris and Kadcyla. Based on mechanism of action, it is divided into CD30 antibodies and HER2 antibodies. Based on application, the market is classified into breast cancer, lymphoma, and others. By geography, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY MARKET BENEFITS

The study provides an in-depth analysis of the market with current trends and future estimations to elucidate the imminent investment pockets.
It offers a quantitative analysis from 2017 to 2023, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
Extensive analysis by product elucidates the various types of ADC’s used for diverse cancer therapeutic procedures
Comprehensive analysis of all geographical regions is provided to determine the prevailing opportunities.
Key players are profiled and their strategies are analyzed thoroughly, which helps understand the competitive outlook of the global ADCs marke.

KEY PLAYERS PROFILED

F. Hoffman-La Roche Ltd.
Novartis AG
Takeda Pharmaceutical Company Limited
Pfizer, Inc.
Seattle Genetics Inc.
Genentech Inc.
Immunogen Inc.
Immunomedics, Inc.
Progenics Pharmaceuticals Inc.
Bayer AG

KEY MARKET SEGMENTS

BY DRUGS

Adcetris
Kadcyla

BY MECHANISM OF ACTION

CD30 Antibodies
HER2 Antibodies

By Application

Breast Cancer
Lymphoma

By Region

North America
U.S.
Canada
Mexico
Europe
France
Germany
UK
Italy
Spain
The Netherlands
Norway
Russia
Sweden
Switzerland
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
New Zealand
Taiwan
Thailand
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Chile
Columbia
Egypt
Iran
Israel
Turkey
Venezuela
Rest of LAMEA

The other players of the anesthesia market include (companies not profiled in the report):

Agensys, Inc.
Concortis Biotherapeutics
Sanofi S.A.
Celldex Therapeutics Inc.
Synthon Holding B.V.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. TOP PLAYER POSITIONING
3.4. PATENTS ANALYSIS

3.4.1. Patent analysis by year
3.4.2. Patent analysis by region

3.5. PORTERS FIVE FORCES ANALYSIS
3.5. MARKET DYNAMICS

3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities

CHAPTER 4 GLOBAL ANTIBODY DRUG CONJUGATES MARKET, BY DRUGS

4.1. OVERVIEW

4.1.1. Market size & forecast

4.2. ADCETRIS

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size & forecast

4.3. KADCYLA

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size & forecast

CHAPTER 5 GLOBAL ANTIBODY DRUG CONJUGATES MARKET, BY MECHANISM OF ACTION

5.1. OVERVIEW

5.1.1. Market size & forecast

5.2. CD30 ANTIBODIES

5.2.1. Market size & forecast

5.3. HER2 ANTIBODIES

5.3.1. Market size & forecast

CHAPTER 6 GLOBAL ANTIBODY DRUG CONJUGATES MARKET, BY APPLICATION

6.1. OVERVIEW

6.1.1. Market size & forecast

6.2. BREAST CANCER

6.2.1. Market size & forecast

6.3. LYMPHOMA

6.3.1. Market size & forecast

CHAPTER 7 GLOBAL ANTIBODY DRUG CONJUGATES MARKET, BY GEOGRAPHY

7.1. OVERVIEW
7.2. NORTH AMERICA

7.2.1. Key market trends
7.2.2. Key growth factors and opportunities
7.2.3. Market size & forecast

7.2.3.1. U.S. market size and forecast
7.2.3.2. Canada market size and forecast
7.2.3.3. Mexico market size and forecast

7.3. EUROPE

7.3.1. Key market trends
7.3.2. Key growth factors and opportunities
7.3.3. Market size & forecast

7.3.3.1. Germany market size and forecast
7.3.3.2. France market size and forecast
7.3.3.3. UK market size and forecast
7.3.3.4. Italy market size and forecast
7.3.3.5. Spain market size and forecast
7.3.3.5. Rest of Europe market size and forecast

7.4. ASIA-PACIFIC

7.4.1. Key market trends
7.4.2. Key growth factors and opportunities
7.4.3. Market size & forecast

7.4.3.1. Japan market size and forecast
7.4.3.2. China market size and forecast
7.4.3.3. Australia market size and forecast
7.4.3.4. India market size and forecast
7.4.3.5. South Korea market size and forecast
7.4.3.5. Taiwan market size and forecast
7.4.3.7. Rest of Asia-Pacific market size and forecast

7.5. LAMEA

7.5.1. Key market trends
7.5.2. Key growth factors and opportunities
7.5.3. Market size & forecast

7.5.3.1. Brazil market size and forecast
7.5.3.2. Turkey market size and forecast
7.5.3.3. Saudi Arabia market size and forecast
7.5.3.4. South Africa market size and forecast
7.5.3.5. Rest of LAMEA market size and forecast

CHAPTER 8 COMPANY PROFILES

8.1. PFIZER, INC.

8.1.1. Operating business segments
8.1.2. Business performance

8.2. CELLDEX THERAPEUTICS INC.

8.2.1. Operating business segments
8.2.2. Business performance
8.2.3. Key strategic moves and developments

8.3. SEATTLE GENETICS INC.

8.3.1. Operating business segments
8.3.2. Business performance
8.3.3. Key strategic moves and developments

8.4. GENENTECH INC.

8.4.1. Operating business segments
8.4.2. Business performance
8.4.3. Key strategic moves and developments

8.5. IMMUNOGEN INC.

8.5.1. Operating business segments
8.5.2. Business performance
8.5.3. Key strategic moves and developments

8.5. SANOFI S.A.

8.5.1. Operating business segments
8.5.2. Business performance
8.5.3. Key strategic moves and developments

8.7. IMMUNOMEDICS, INC.

8.7.1. Operating business segments
8.7.2. Business performance
8.7.3. Key strategic moves and developments

8.8. PROGENICS PHARMACEUTICALS INC.

8.8.1. Operating business segments
8.8.2. Business performance
8.8.3. Key strategic moves and developments

8.8. BAYER HEALTHCARE PHARMACEUTICALS

8.8.1. Operating business segments
8.8.2. Business performance
8.8.3. Key strategic moves and developments

8.10. SYNTHON HOLDING B.V.

8.10.1. Operating business segments
8.10.2. Business performance
8.10.3. Key strategic moves and developments
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll